Evaluation of tumor response three months after concomitant chemoradiotherapy with high dose rate brachytherapy as a definitive treatment modality for locally advanced cervical cancer

Bull Cancer. 2022 Mar;109(3):280-286. doi: 10.1016/j.bulcan.2021.08.012. Epub 2021 Nov 11.


Objective: Radiotherapy remains an essential part of the management of locally advanced cervical cancer. Post-treatment surveillance allows for tumor response assessment and early detection of progressive prosecutions or local recurrences that may benefit from salvage treatment. The objective of this work is to assess the effectiveness of this therapeutic modality.

Materials methods: This is a retrospective study of 69 patients treated with concomitant radiation chemotherapy followed by high dose rate intracavitary brachytherapy. The tumor response was assessed by gynecologic physical examination at three months after the end of treatment.

Results: Median age of patients is 54.9 years (33-78 years). The most common histological type is squamous cell carcinoma (89.9%). The average dose received during external radiotherapy is 52.2Gy (46-60Gy). The average dose received during brachytherapy is 27.5Gy (18-28Gy). Three months after completion of treatment, 95.6% of patients had complete tumor remission, and only 4.4% had a tumor residue of 1cm.

Conclusion: Radiation chemotherapy with brachytherapy allows for improved short-term local control in cervical cancer.

Keywords: Cervical cancer; Complete response; Concomitant chemoradiotherapy; Efficacy; Intracavitary brachytherapy; Short-term local control.

MeSH terms

  • Adult
  • Aged
  • Brachytherapy* / methods
  • Chemoradiotherapy*
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / therapy*